Cargando…

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

Central nervous system (CNS) metastases occur frequently in oncogene-driven non-small cell lung cancer (NSCLC). Standard treatment approaches can potentially delay systemic treatment (surgical intervention) or result in neurocognitive impairment (radiotherapy). Recently, next-generation tyrosine kin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gal, Omer, Dudnik, Elizabeth, Rotem, Ofer, Finkel, Inbar, Peretz, Idit, Zer, Alona, Mandel, Jacob, Amiel, Alexandra, Siegal, Tali, Bar, Jair, Lobachov, Anastasiya, Yust, Shlomit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486631/ https://www.ncbi.nlm.nih.gov/pubmed/32963526 http://dx.doi.org/10.1155/2020/1980891

Ejemplares similares

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
por: Landman, Yosef, et al.
Publicado: (2021)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

Long term follow-up of EGFR mutated NSCLC cases
por: Rennert, Gad, et al.
Publicado: (2020)

Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study
por: Massarweh, Amir, et al.
Publicado: (2022)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

Height as a risk factor in meningioma: a study of 2 million Israeli adolescents
por: Ben-Zion Berliner, Matan, et al.
Publicado: (2020)

Significant Systemic Insulin Resistance is Associated With Unique Glioblastoma Multiforme Phenotype
por: Laviv, Yosef, et al.
Publicado: (2023)

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course
por: Tschernichovsky, Roi, et al.
Publicado: (2023)

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
por: Zer, Alona, et al.
Publicado: (2014)

Potential Association between Kaposi Sarcoma and Gout: An Exploratory Observational Study
por: Moore, Assaf, et al.
Publicado: (2020)

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit
por: Haberman, Yael, et al.
Publicado: (2023)

Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the literature
por: Averbuch, Itamar, et al.
Publicado: (2023)

Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy
por: Rotem, Ofer, et al.
Publicado: (2023)

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone
por: Saad, Akram, et al.
Publicado: (2022)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
por: Piper-Vallillo, A.J., et al.
Publicado: (2022)

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
por: Suidan, Anna May, et al.
Publicado: (2019)

Paraneoplastic syndromes in small cell lung cancer
por: Soomro, Zaid, et al.
Publicado: (2020)

Selective Intra-Arterial Doxorubicin Eluting Microsphere Embolization for Desmoid Fibromatosis: A Combined Prospective and Retrospective Study
por: Elnekave, Eldad, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Primary Lung Cancer in Recipients of Lung Transplant
por: Moore, Assaf, et al.
Publicado: (2020)

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience
por: Moore, Assaf, et al.
Publicado: (2021)

MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma
por: Pillar, Nir, et al.
Publicado: (2017)

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
por: Gadgeel, Shirish, et al.
Publicado: (2018)

Intensity‐modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma
por: Simon, Michael, et al.
Publicado: (2018)

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
por: Harel, Michal, et al.
Publicado: (2022)

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
por: Illini, Oliver, et al.
Publicado: (2022)

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
por: Icht, Oded, et al.
Publicado: (2023)

Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study
por: Rotem, Ofer, et al.
Publicado: (2023)

Elemene treatment for NSCLC with multiple CNS metastases: a case report and literature review
por: Han, Yushan, et al.
Publicado: (2018)

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience
por: Purim, Ofer, et al.
Publicado: (2018)

A Novel Approach to Vaccine Development: Concomitant Pathogen Inactivation and Host Immune Stimulation by Peroxynitrite
por: Rotem, Shahar, et al.
Publicado: (2022)

Characterization of tumor infiltrating Natural Killer cell subset
por: Levi, Inbar, et al.
Publicado: (2015)

Evolutionary Conservation and Transcriptome Analyses Attribute Perenniality and Flowering to Day-Length Responsive Genes in Bulbous Barley (Hordeum bulbosum)
por: Fuerst, Dana, et al.
Publicado: (2022)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

Protective Immunity against Lethal F. tularensis holarctica LVS Provided by Vaccination with Selected Novel CD8(+) T Cell Epitopes
por: Rotem, Shahar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4n2001t83d86e1due4f7phn3oq